First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Haemophilia

Volumn 22, Issue 1, 2016, Pages 87-95

  Kreuz, W ^a   Escuriola Ettingshausen, C ^a   Vdovin, V ^b   Zozulya, N ^c   Plyushch, O ^c   Svirin, P ^b   Andreeva, T ^d   Bubanska E ^e   Campos, M ^f   Benedik Dolnicar M ^g   Jimenez Yuste V ^h   Kitanovski, L ^g   Klukowska, A ⁱ   Momot, A ^j   Osmulskaya, N ^k   Prieto, M ^l   Salek S Z ^m   Velasco, F ⁿ   Pavlova, A ^o   Oldenburg, J ^o   Knaub, S ^p   Jansen, M ^q   Belyanskaya, L ^p   Walter, O ^p   Auerswald, G ^r   Batorova A ^r   Benz Lemoine, E ^r   Buhrlen M ^r   Berger, C ^r   Boggia, B ^r   Carvalho, M ^r   Chan, A K C ^r   Felipe, C ^r   Hak, J ^r   Henni, T ^r   Joao Diniz M ^r   Kenet, G ^r   Klimova, N ^r   Komrska, V ^r   Lassila, R ^r   Lopes Tavares, A ^r   Mamaev, A N ^r   Martinez Saguer, I ^r   Morais, S ^r   Montano Mejia A C ^r   Pluyusch, O ^r   Prunnsild, K ^r   Pyatkova, O ^r   Quintana Molina, M ^r   Nowak Gottl U ^r   Rodriguez, I ^r   Rosado, L ^r   Rothschild, C ^r   Severova, T ^r   Shiller, E ^r   Sol Cruz, M ^r   Teixeira, A ^r   Astermark, J ^r   Berntorp, E ^r   Dargaud, Y ^r   Lacroix Desmazes, S ^r   Negrier C ^r   more..

^a HZRM   (Germany)

^b Izmaylovo Children's Hospital Haematological Centre   (Russian Federation)

^c NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^d St Petersburg State Health Care Institution   (Russian Federation)

^e Children's Faculty Hospital L   (Slovakia)

^f HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^g UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j Altai Hematological Center   (Russian Federation)

^k Omsk Regional Institute   (Russian Federation)

^l HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^m KBC Zagreb   (Croatia)

ⁿ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^o UNIVERSITY HOSPITAL BONN   (Germany)

^p Octapharma AG   (Switzerland)

^q Octapharma Pharmazeutika Produktions GmbH   (Austria)

^r NONE

more..

Author keywords

Bonn protocol; Factor VIII inhibitors; Factor VIII von Willebrand factor concentrate; Haemophilia A; Immune tolerance induction; Poor prognosis for immune tolerance induction

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; NEUTRALIZING ANTIBODY; BLOOD CLOTTING FACTOR 8; DRUG COMBINATION; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; VON WILLEBRAND FACTOR;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; FEVER; GINGIVITIS; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS CATHETER; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SKIN ALLERGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; BLEEDING; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; SAFETY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SAFETY; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84958833925     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12774     Document Type: Article

References (30)

1. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
3. Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
4. Escuriola Ettingshausen C, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophila 2010; 16: 90-100.
5. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
6. Blanchette VS, Key NS, Ljung LR et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935-9.
7. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 203-6.
8. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn protocol'. Vox Sang 1996; 70: 30-5.
9. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
10. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
11. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
12. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
13. Kreuz W, Joseph-Steiner J, Mentzer D. Successful immune tolerance therapy of FVIII-inhibitors in children after changing from high to intermediate purity FVIII concentrate. Ann Hematol 1996; 72: 339.
14. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13: 73-7.
15. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
16. Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost 2013; 109: 464-70.
17. Schwarz J, Astermark J, Menius ED et al. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 2013; 19: 113-8.
18. Kreuz W, Escuriola Ettingshausen C, Auerswald G et al. Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success. Haematologica 2001; 86: 16-22.
19. Berntorp E, Eckman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
20. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
21. Hay CR, Di Michele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
22. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
23. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
24. Santagostino E. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance. Haemophilia 2013; 19: 8-11.
25. Kurth M, Puetz J, Kouides P et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-34.
26. Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia 2014; 20: 83-91.
27. Di Michele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 1): 1-22.
28. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.
29. Di Michele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-8.
30. Di Minno G, Coppola A. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution? Haemophilia 2013; 19: 18-23.